CRISPR Therapeutics' GAAP net income for 6 months of 2021 was $646.062 million, compared to a loss of $149.387 million in the previous year. Revenue increased multiple times to $901.24 million from $0.201 million a year earlier.
CRISPR Therapeutics' GAAP net income for 6 months of 2021 was $646.062 million, compared to a loss of $149.387 million in the previous year. Revenue increased multiple times to $901.24 million from $0.201 million a year earlier. 
ir.crisprtx.com
English (US) 